Summing up our work, we are proposing three strategies for an in depth investigation in preclinical models of ovarian cancer using immune-compromised mice and cells that exhibit low Caspase-8 expression and resistance to Carboplatin and/or Paclitaxel—combinations of (1) Carboplatin with small-molecule BRD4 inhibitors; (2) Paclitaxel with small-molecule BRD4 inhibitors; and (3) small-molecule BRD4 and CDK9 inhibitors. The gene discussed is CDK9; the disease is ovarian cancer.